SC0062 strength 10mg

DRUG2 trials

Sponsors

University Medical Center Groningen, Biocity Biopharmaceutics Co., Ltd.

Conditions

IgA Nephropathy (IgAN)Type 1 Diabetes Mellitus With Diabetic Nephropathy

Phase 2

dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation

Not yet recruitingNCT06072326

University Medical Center GroningenType 1 Diabetes Mellitus With Diabetic Nephropathy

Start: 2026-01-31End: 2028-12-31Target: 36Updated: 2025-10-07

Phase 3

A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria

RecruitingNCT06819826

Biocity Biopharmaceutics Co., Ltd.IgA Nephropathy (IgAN)

Start: 2025-02-14End: 2028-12-31Target: 360Updated: 2025-02-17